Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features

• Mihir D. Wechalekar,
• Lin-Pierre Zhao,
• Monika M. Kutyna,
• Lih En Hong,
• Joule Li,
• Kevin Hung,
• Hamish S. Scott,
• Anna Brown,
• Christopher C. Hahn,
• Karin Kassahn,
• Dariusz Ladon,
• David T. Yeung,
• Daniel Thomas,
• Mrinal Patnaik,
• Susanna Proudman,
• Lionel Ades,
• Mithun V. Shah,
• Chung H. Kok,
• Devendra K. Hiwase

Affiliations

Mihir D. Wechalekar

Rheumatology Unit, Flinders Medical Centre

Lin-Pierre Zhao

Department of Hematology, Hôpital Saint-Louis, Université de Paris, Assistance Publique des Hôpitaux de Paris (AP-HP)

Monika M. Kutyna

Haematology Department, Central Adelaide Local Health Network

Lih En Hong

Rheumatology Unit, Royal Adelaide Hospital

Joule Li

Department of Medicine, Royal Adelaide Hospital

Kevin Hung

Haematology Department, Central Adelaide Local Health Network

Hamish S. Scott

Adelaide Medical School, University of Adelaide

Anna Brown

Adelaide Medical School, University of Adelaide

Christopher C. Hahn

Adelaide Medical School, University of Adelaide

Karin Kassahn

Genetics and Molecular Pathology, SA Pathology

Dariusz Ladon

Genetics and Molecular Pathology, SA Pathology

David T. Yeung

Haematology Department, Central Adelaide Local Health Network

Daniel Thomas

Haematology Department, Central Adelaide Local Health Network

Mrinal Patnaik

Division of Hematology, Mayo Clinic

Susanna Proudman

Rheumatology Unit, Royal Adelaide Hospital

Lionel Ades

Department of Hematology, Hôpital Saint-Louis, Université de Paris, Assistance Publique des Hôpitaux de Paris (AP-HP)

Mithun V. Shah

Division of Hematology, Mayo Clinic

Chung H. Kok

Adelaide Medical School, University of Adelaide

Devendra K. Hiwase

Haematology Department, Central Adelaide Local Health Network